China (Mainland)
Assessedsupplier 
Raloxifene CAS NO.84449-90-1
- Min.Order: 500 Gram
- Payment Terms: T/T,Other
- Product Details
Keywords
- Raloxifene
- 84449-90-1
- Raloxifene,CAS no 84449-90-1
Quick Details
- ProName: Raloxifene
- CasNo: 84449-90-1
- Molecular Formula: C28H27NO4S
- Appearance: solid or liquid
- Application: for pharma use
- DeliveryTime: Prompt
- PackAge: drum and bag
- Port: Beijing or Guangzhou
- ProductionCapacity: 1 Metric Ton/Year
- Purity: 99.90%
- Storage: in sealed air resistant place
- Transportation: by sea or air
- LimitNum: 500 Gram
- Related Substances: NMT0.001%
- Residue on Ignition: 0.00%
- Heavy Metal: NMT1ppm
- Valid Period: 2 years
Superiority
Details
Introduction:
Raloxifene (marketed as Evista by Eli Lilly and Company) is an oral selective estrogen receptor modulator (SERM) that has estrogenic actions on bone and anti-estrogenic actions on the uterus and breast. It is used in the prevention of osteoporosis in postmenopausal women and to reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer.
Specification:
|
Items |
Standard |
Results |
|
|
Appearance |
Yellowish powder |
Comply |
|
|
Identification
|
IR |
Comply |
|
|
It meets the requirements of the test for Choride |
Comply |
||
|
Solubility |
Soluble in 10% sodium hydroxide solution, slightly soluble in methanol, insoluble in water |
Comply |
|
|
Assay |
98.5%~101.5% |
99.27% |
|
|
Related Substances |
≤0.20% RRT=0.74 impurity |
≤0.2% |
Comply |
|
Other single impurity |
≤0.1% |
0.09% |
|
|
Total impurities |
≤0.5% |
0.36% |
|
|
Loss on drying |
≤0.5% |
0.08% |
|
|
Residue on ignition |
≤0.1% |
Comply |
|
|
Heavy metals |
≤10ppm |
Comply |
|
|
Storage |
Preserve in well-closed containers and Protected from light. Store at room temperature |
||
|
Determination |
Complies with USP32 standard |
||
Medical use
Raloxifene is indicated for the treatment and prevention of osteoporosis in postmenopausal women. It is also used for reduction of risk and treatment of invasive breast cancer, and it also reduces breast density.For either osteoporosis treatment or prevention, supplemental calcium and/or vitamin D should be added to the diet if daily intake is inadequate.